The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

The good news, I guess, is that we have very many different treatment options for relapse refractory multiple myeloma, and some of that is considered in the background of what we do for patients with ...

Creative Biolabs has a professional platform that provides customized CAR construction and design, meeting diverse needs of CAR-T cell therapy resear ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine discusses key takeaways from the ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of ...

Fresenius announced that its operating company, Fresenius Kabi, has introduced two new biosimilars – Conexxence ...

Researchers have identified ways in which chemotherapy can damage healthy cells and found that some drugs can add decades of ...

Fresenius announced today that its operating company Fresenius Kabi, has introduced two new biosimilars - Conexxence® ...

Antibody-Drug Conjugates (ADC) Market- Driven by Advanced Payload Technologies and Strategic Industry Partnerships Sai Kumar DataM Intelligence 4market Research LLP +1 877-441-4866 ... Visit us on ...